Quarterly ResultAug 5, 2026, 04:20 PM
Myomo Q2 Revenue +21% to $11.7M; Raises FY Guidance to $45-47M
AI Summary
Myomo, Inc. reported strong financial results for the second quarter ended June 30, 2026, with revenue reaching $11.7 million, a 21% increase year-over-year, exceeding expectations. The company demonstrated significant operating leverage, with gross margin expanding to 72.1% and Adjusted EBITDA loss improving by 79% to $0.8 million. Driven by the success of its go-to-market approach and growing clinical referral network, Myomo raised its full-year revenue guidance to $45 million to $47 million.
Key Highlights
- Q2 2026 revenue was $11.7 million, a 21% increase year-over-year.
- Gross margin expanded to 72.1% in Q2 2026, up from 62.7% in Q2 2025.
- Operating expenses increased less than 1% year-over-year to $10.7 million.
- Net loss for Q2 2026 was $4.0 million, or $0.09 per share.
- Adjusted EBITDA loss improved by 79% to $0.8 million in Q2 2026.
- Full-year revenue guidance raised to $45 million to $47 million.
- Cash used in operating activities was $1.9 million for Q2 2026, down from $8.9 million in Q2 2025.
- Added 739 patients to the pipeline and recorded 255 orders in Q2, up 23% year-over-year.
Price Impact
More from MYO